High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm
Posted inInfectious Diseases Neurology news

High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm

A multinational randomized trial found that adding high‑dose oral rifampin (total 35 mg/kg for 8 weeks) to standard therapy did not reduce 6‑month mortality in adults with tuberculous meningitis and was associated with more drug‑induced liver injury and earlier deaths in some patients.
Shorter Is Safe: Adjusted Analyses of BALANCE Confirm Non‑Inferiority of 7‑Day Antibiotic Courses for Uncomplicated Bloodstream Infection
Posted inInfectious Diseases news

Shorter Is Safe: Adjusted Analyses of BALANCE Confirm Non‑Inferiority of 7‑Day Antibiotic Courses for Uncomplicated Bloodstream Infection

A post-hoc analysis of the BALANCE randomized trial shows that after accounting for treatment non-adherence using causal inference methods, 7 days of antibiotics for uncomplicated non‑Staphylococcus aureus bloodstream infection remains non‑inferior to 14 days for 90‑day mortality.